This drug undergoes an important hepatic metabolism in humans giving N-hydroxycetocyclobutylmethyl nornalbuphine, the major metabolite, and hydroxylated derivatives. 1 The estimated hepatic extraction ratio of nalbuphine is 0.5 -0.7; thus, its hepatic clearance will be mainly dependent on hepatic blood flow. 4 5 Pharmacokinetic data of this drug are limited; studies have been carried out in adults, children, and neonates. 4 6-8 It is well known that the pharmacokinetics of most drugs are agedependent. 9 -11 Maturation of metabolic pathways takes place at a different rate; the metabolic clearance of drugs is usually very low at birth and then increases to reach a maximum at about the age of 1 yr when it can exceed that of adults. Simultaneously, water compartments are significantly larger in children than in adults. Thus, the treatment of postoperative pain by drugs extensively metabolized in the liver raises a challenge to the clinician who takes care of them.
Although nalbuphine has been approved for clinical use in children, pharmacokinetic data of the drug remain very limited. Nicolle and colleagues 7 reported data for a few neonates whose mothers had received nalbuphine during labour. Jacqz-Aigrain and colleagues 8 have reported data of a population pharmacokinetic study carried out in neonates. These authors found that birth weight is a major determinant of variability in nalbuphine disposition. Jaillon and colleagues 4 have shown that the elimination half-life of nalbuphine is shorter in infants of 1.5-5 yr of age than in those of 5-8.5 yr and that systemic clearance per kilogram of body weight decreased with age. However, only seven infants have been included in each group. The present study was designed to provide data on pharmacokinetics of nalbuphine in a paediatric population aged 1-11 yr old. The purpose of this study was (i) to determine accurate population pharmacokinetic parameters by using a two-compartment open model; this model was parameterized in terms of total clearance, central volume of distribution, inter-compartment clearance, and peripheral volume of distribution, (ii) to accurately estimate both inter-and residual variability in pharmacokinetic parameters, and (iii) to identify which of the patient physiological parameters could have influenced drug disposition. These data provide further valuable information regarding appropriate paediatric dosing.
Methods

Study design
The study protocol was reviewed and approved by the institutional review board. It was performed in accordance with the legal requirements and the Declaration of Helsinki, and with current European Community and US Food and Drug Administration guidelines for good clinical practice. Written informed consent was obtained from the parents or legal guardians. Twenty-two infants undergoing laparoscopic fundoplication for gastro-oesophageal reflux aged 1-11 yr were included in this study. They were admitted in the department of paediatric surgery of the Lapeyronie Hospital (Montpellier, France). For all children, pre-anaesthetic data, anamnestic data, physical examination, and standard laboratory tests which included haematological and biochemical tests were performed before and at the end of the study. Each subject's measurements of alanine aminotransferase, aspartate aminotransferase, bilirubin (direct bilirubinaemia ,2 mg dl 21 
Blood sampling
It was planned to collect heparinized blood samples (2.5 ml) from each patient at the following times: (i) immediately before and (ii) at the end of the loading dose, (iii) 12 and 24 h after the beginning of i.v. infusion, and (iv) 0.25, 0.5, 1, 2, 4, 6, and 12 h after the end of infusion. Immediately after collection, plasma was separated by centrifugation (1500g) within 10 min and was frozen at 2308C until assayed.
Nalbuphine assay
Nalbuphine was quantified in human plasma by highperformance liquid chromatography using tandem-mass spectrometry detection (LC-MS/MS). The internal standard used was morphine. The LC system equipped with an autosampler set at 48C was coupled to a PE Sciex API 365 quadrupole MS (Applied Biosystem MDS Sciex, Courtaboeuf, France) with a turbo electrospray ion source that was operated in a positive ionization mode with the nebulizer and TurboIonSpray gases (nitrogen) set at 12 and 30 pounds per square inch (psi), respectively. The voltage and temperature were maintained at 4500 V and 2508C, respectively. Nitrogen gas was used in a collision-induced dissociation at a back pressure of approximately level 6. Nalbuphine was quantified via a multiple reaction monitoring mode of the transitions at m/z 21 . A 10 ml sample was injected onto the column. Samples were extracted using the solid-phase extraction (SPE) automate Aspec XL4 on Bond Elut C18 (100 mg) cartridges. SPE cartridges were first conditioned with 1 ml of methanol, 1 ml of distilled water, and 1 ml of Tris-buffered saline solution (pH 7.5) and then plasma samples were loaded onto the cartridges. The column was then rinsed with 1 ml of distilled water. The elution was carried out with 1 ml of a mixture of acetonitrile -water (80:20, v/v) containing 1% formic acid. The organic phase was evaporated under a stream of nitrogen at 408C. The peak area ratios (nalbuphine/internal standard) varied linearly with concentration over the range of 1-100 mg litre 21 . All calibration curves were weighted according to the 1/x 2 weighting scheme. The method was precise (precision, ≤12%) and accurate (recovery, 91-100%). Mean extraction efficiencies .80% for each analyte were obtained. No significant matrix effects occurred. Dilution has no influence on the performance of the method. The lower limit of quantitation (LLOQ) was 1 mg litre 21 .
Pharmacokinetic analysis
Pharmacokinetic model-building analyses were performed using the non-linear mixed-effects modelling (NONMEM) software (version 5.1.1, Globomax LLC, Hanover, MD, USA) 13 through the Visual-NM graphical interface. 14 The following covariates were considered pertinent to this study: patients' age, body surface area, weight, height, gender, and the ASA score (physical status classification system before surgery). A two-compartment model fitted data better than a one-or a three-compartment pharmacokinetic model. This model was parameterized in terms of total clearance (CL), central volume of distribution (V 1 ), inter-compartment clearance (Q), and peripheral volume of distribution (V 2 ). First-order conditional estimation was used to fit the models because individual data sets were extensive. 13 The structural model was chosen on the basis of changes in 22 log-likelihood and on graphical analyses of the goodness of fit. Because 22 log-likelihood is approximately x 2 distributed and the addition of one compartment increases the degree of freedom by a factor of 4, a change of 9.49 in 22 log-likelihood was required at the 5% significance level to select the more complex model. Several error models were compared: additive, exponential, or combined (additive+ exponential). It was found that residual variability was best described by an exponential error model given below:
where P j is the pharmacokinetic parameter of the subject j, t ij the time of the ith measurement, D j the dosing history of the subject j, f the pharmacokinetic model, and 1 ij the residual deviation of the model from the observations and contains contributions from intra-individual variability, assay error, and model misspecification for the dependent variable. 1 is assumed to be a random Gaussian variable with mean zero and variance of v 2 1 . Inter-individual variability in pharmacokinetic parameters was assessed according to an exponential error model; the P j parameter of the jth subject was described by the relationship:
where P j is the pharmacokinetic parameter of subject j, P mean the population pharmacokinetic parameter, and h P a Gaussian random variable with mean zero and variance of v 2 hP . Individual parameters were calculated as empirical Bayes estimates using the POSTHOC option in NONMEM. Several secondary pharmacokinetic parameters were calculated from the individual primary pharmacokinetic parameters: the volume of distribution at steady-state (V ss ) and the halflife (t 1/2 ) of the terminal part of the curves.
After selection of the best basic pharmacostatistical model, both a traditional approach and an allometric scaling were used to test the influence of covariates. In a first step, the relationships between the individual pharmacokinetic parameters and the above-mentioned covariates were investigated graphically. Covariates showing a strong correlation with a pharmacokinetic parameter were then separately incorporated in the population model and tested for statistical significance. Both linear functions and power models were tested (covariates being centred or not around the mean values). The effect of each covariate was assessed by the likelihood ratio test, based on the difference in the objective function values between hierarchical models. The forward inclusion and backward elimination method was applied for covariate model development.
In a second step, allometric scaling 15 -17 was also tested to assess the influence of weight on CL, Q, V 1 , and V 2 :
with g¼0.75 for clearances and g¼1 for volumes of distribution. In this equation, Param j is the parameter in the jth individual with a weight of WT j and Param std the parameter in an individual with a weight of 70 kg (WT 70 kg ).
Quality of fit
Criteria for model selection included visual inspection of goodness-of-fit plots [i.e. measured concentrations (DV) vs population (PRED) and individual predictions (IPRED); weighted residuals (WRES) vs PRED; and WRES vs time after administration]. The performance of Bayesian estimation was assessed by examining the prediction error (PE); PE was defined as [(DV-IPRED or PRED)/IPRED or PRED]×100%. Both MDPE (median of all PEs) and MDAPE (median of all absolute PEs) were calculated.
Using the final covariate model, the visual predictive checks (VPCs) were carried out by simulating 1000 virtual data sets to assess the performance of the model. This analysis was performed using the R program. The 5th, 50th (population median response), and 95th percentile concentrations were plotted against time post-dose and the patients' data were superimposed.
Simulations
We selected an average concentration of 12 mg litre 21 as the therapeutic concentration for the design of an effective dosing regimen for nalbuphine. This concentration corresponds to the mean steady-state plasma concentration observed in this study. Simulations were performed using parameters of the final model to determine the optimal treatment schedule of nalbuphine needed to maintain this concentration. Typical patients of weight 10 kg (1-2 yr old), 13 kg (2-5 yr old), and 24 kg (5-11 yr old) were assumed for simulation purposes. Moreover, we have characterized the pharmacokinetics of elimination of nalbuphine in terms of the 20%, 50%, and 80% context-sensitive decrement times.
Validation of the final model
The bootstrap resampling procedure was used for evaluating the stability and robustness of the final model. 18 The bootstrap resampling was repeated 1000 times to evaluate whether an appreciable discrepancy existed between the parameter values estimated from the original data and the estimated bootstrap mean values. Final population parameters were compared with those obtained from the 1000 bootstrap analyses.
Results
All patients received planned continuous analgesia and no therapeutic failure (i.e. shift to morphine) was observed. There were 14 patients (63.6%) who required at least one additional bolus of nalbuphine. This first bolus was given at a mean time of 2.2 h after surgery (SD: 2.3 h). Nine patients (41.0%) received a second bolus at 7.4 h, seven received a third bolus at 10.0 h, three a fourth bolus at 12.6 h, and one a fifth bolus at 19.8 h. All resulted in a decrease in CHIPPS from 6.5 down to 0.7 within 30 min. Drowsiness was observed in seven patients (31.8%), nausea in three (13.6%), and urinary retention in three. Out of 22 children enrolled in the study, two were excluded for lack of blood samples. Baseline patient characteristics of the 20 children (six girls and 14 boys) who completed the study are presented in Table 1 . Eight children had an ASA score of I, 10 had an ASA score of II, and two had an ASA score of III. Depending on the patient, 4-6 h after the end of infusion, nalbuphine concentrations were below the LLOQ of the analytical method. Therefore, a total of 157 plasma concentration measurements were included in the analysis.
A decrease in the objective function of 60.6 is associated with the use of a two-compartment model compared with a one-compartment model. The use of a three-compartment model led to failure in model convergence. Before covariate inclusion (Step 1), population pharmacokinetic parameters are summarized in Table 2 . During covariate analysis, two models gave good results: (i) the addition of weight and age on CL [CL¼weight×(2age×u 1 +u 2 )] and age on V 1 [V 1 = u 3 × age/4.2 u 4 ] to the base model produced a decrease in objective function of 44.6 units; and (ii) the use of allometric scaling results in an improvement of the objective function of 39.3 units. For both models, the fits to the data were excellent and the differences were relatively small. As the first model has two more parameters than the allometric model, it is not statistically better. Moreover, criteria on the quality of fit were slightly better for the allometric model. Thus, this model was selected as the final model. The estimated population parameters of nalbuphine in the final model are shown in Table 2 . It was not possible to estimate population parameter variability on V 2 . The ratios of the between-subject variance predictable from covariates to the total population parameter variance obtained without covariate analysis are presented in Table 3 . Inclusion of body weight decreased the variance of CL and V 1 , but increased the variance of Q. A reason may be that there is no v for V 2 (having a large variance of 0.473 in the basic model) in the allometric model, so that the high variance of Q may in part be attributable to V 2 . Results presented in Table 3 indicate that 39% and 65% of the overall variability in V 1 and CL are predictable from covariate information, respectively. 19 Mean pharmacokinetic parameters of nalbuphine in the 20 children who completed this study are presented in Table 4 . The elimination half-life of nalbuphine increased with age (from 1.7 h in 1-to 2-yr-old children to 3.5 h in 7-11 yr old) and the CL in litre h 21 Fig. S1B ). Nalbuphine pharmacokinetics in children Moreover, adequate plots were observed in the final model between weighted residuals and predicted concentrations ( Supplementary Fig. S1C ). The vast majority of the weighted residuals lay within 2 units of perfect agreement and were symmetrically distributed around the zero ordinate; no systematic deviations were observed. For the final model, the MDPE and MDAPE of the population predictions PRED were 20.40% and 22.8%, respectively (Table 2) . These values were in a typical range for pharmacokinetic models. The plot of PEs vs time shows random distribution around the zero ordinate (data not shown). The VPC plot (Fig. 2) confirms the adequacy of model predictions, showing no apparent deviations between model and data. About 95% of the data fit well within the 5th -95th percentiles band and the data were symmetrically distributed around the median. The time-concentration profile (with 90% CI) for a 4-yr-old child weighing 16 kg is presented in Figure 3 . The final model was fitted repeatedly to 1000 bootstrap-resampled data sets. Less than 6% of bootstrap runs were unsuccessful. The average parameter values obtained from the bootstrap analyses and the final estimates from the original data set are compared in Table 6 . These results indicated that the reliability and robustness of the parameter estimates and thus the population pharmacokinetic model was acceptable.
Discussion
The present study was undertaken in the light of the limited information regarding pharmacokinetics of nalbuphine in children. 4 7 8 With the exception of neonates, 8 these published studies have been performed in a limited number of subjects. 4 7 Both NONMEM and non-parametric expectation maximization methods have been used for population pharmacokinetic modelling in children. In this study, nalbuphine population characteristics were estimated using NONMEM. This population modelling method described nalbuphine data well. Different pharmacokinetic models were tested; the structural model was chosen on the basis of the changes in 22 log-likelihood and qualitative assessment of diagnostic plots. Contrary to the findings reported by Jacqz-Aigrain and colleagues, 8 a two-compartment model was found to fit the data satisfactorily. This model was in agreement with that published by Jaillon and colleagues. 4 The number of patients finally included in this study was 20. In infants having about the same age, there are marked inter-patient variations in weight (e.g. in patients between 3 and 4 yr of age, the body weight ranged from 8 to 15 kg). These results were in agreement with those reported by Jacqz-Aigrain and colleagues 8 in neonates. It has been suggested that the use of allometric models in Time ( children well described the relationships between clearances and weight and volumes of distribution and weight. 15 -17 19 In the current study, different covariate models were examined: the traditional approach using a linear or power model and the allometric model. The best results were obtained using the allometric model. Such a parameterization avoids additional parameters in the model and allows a comparison of children parameter estimates with those reported in adults and neonates. A large proportion of the parameter variability (39% and 65% of the overall variability in V 1 and CL, respectively) can be attributable to the inclusion of weight in the model. In our population of children, the mean CL was 41. decreased significantly with age ( Fig. 1 ) and the elimination half-life significantly increased. At the age of 11 yr, children have a CL about two times lower than at the age of 1 yr. In the present study, V ss and the elimination half-life were 1.5-2 times higher than that reported by Jaillon and colleagues. 4 The population model developed in this study predicts nalbuphine plasma concentrations accurately and with good precision as evidenced by small MDPE and MDAPE values (20.4% and 22.8%, respectively) and the results of the VPC plots. The result of bootstrap analysis validation indicated that the reliability and robustness of the parameter estimates and thus the population pharmacokinetic model was acceptable.
Patients who completed the study received administered doses of nalbuphine ranging from 1 to 1. 4 Overall, the treatment was well tolerated by the children and none of them required morphine rescue analgesia.
Patients of this study received co-administration of midazolam, propofol, remifentanil, sevoflurane, and acetaminophen. Nalbuphine is metabolized via cytochrome P-450 3A4 (CYP3A4) and 2C19. 20 CYP3A4 is responsible for the metabolism of numerous therapeutic drugs including midazolam and acetaminophen. 21 22 Anaesthetic agents-remifentanil, propofol, and sevoflurane-were selected to avoid clinical interference with pain evaluation and proved rapid elimination. Midazolam also had a short elimination half-life, between 1.5 and 2.5 h and was given at least 3 h before nalbuphine. 23 Acetaminophen was administered after surgery, four times a day; it is likely that therapeutic blood levels are much higher than those of nalbuphine. Thus, a risk of non-competitive inhibition of the metabolism of nalbuphine by acetaminophen, as previously reported for fentanyl, 24 might occur. However, in clinical practice, acetaminophen is routinely associated with opioid analgesics as part of multimodal analgesic procedures; nalbuphine-acetaminophen drug interactions have never been reported. Concerning the other co-administered drugs, there is no risk of pharmacokinetic interactions.
In conclusion, we reported for the first time the results of a population pharmacokinetic analysis carried out in children to estimate individual pharmacokinetic parameters of nalbuphine. This study demonstrates the importance of considering and incorporating weight as a covariate in order to adequately describe the drug behaviour. The allometric power model developed in this study best reflected the data and may be useful for dose adjustment.
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